peptideInjectableNot FDA-approvedResearch chemicalNot FDA-approved; RegeneRx-sponsored early-phase trials of Tβ4 derivatives (e.g., RGN-137) have been conducted for dermal wounds but no product has reached approvalSold in some markets as an unregulated research peptide; the 2026 sports-medicine review flags it among unapproved peptides marketed direct to patients
Thymosin Beta-4Benefits, Dosage & Interactions
Also known as: TB4
Thymosin Beta-4 (TB4) is a naturally occurring peptide composed of 43 amino acids, found in various tissues and cell types throughout the body. It belongs to the thymosin family of peptides, which are involved in a wide range of cellular processes.
How much Thymosin Beta-4 do people take?
The cited reviews describe animal and early-phase human wound-healing studies (e.g., dermal and corneal repair) without a single agreed dose; no controlled human RCT dosing data were located. Route reported: Topical or subcutaneous/parenteral administration depending on the model, per the regenerative-peptide review. Frequency reported: Not established by a completed human randomized trial. These are amounts documented in the cited studies and labels for Thymosin Beta-4 — they are reported for reference, not a recommendation. Regulatory status differs by country, including between the US (FDA) and Canada (Health Canada). Confirm any amount with a licensed clinician before you take it.
See the full reported protocol and its sourcesResearched by DoseRoutine Research TeamReviewed for accuracy by Nicholas Alexander, RSE, SO, PMPLast updated Educational reference only — not medical advice. Always confirm dosing and safety decisions with a licensed clinician.
Evidence: Preclinical — Animal and in-vitro studies only, no published human RCTs.
Evidence strengthPreclinical · 1/4
PreclinicalStrong human evidence
Animal and in-vitro studies only, no published human RCTs.
Plasma half-life
Reported as cleared from circulation on the order of minutes to a few hours based on beta-thymosin turnover studies
Default unit
mg
What published protocols report
Ranges documented in the literature, shown for reference. DoseRoutine does not recommend an amount — your prescriber or the product label sets the dose.
- Reported amounts
- The cited reviews describe animal and early-phase human wound-healing studies (e.g., dermal and corneal repair) without a single agreed dose; no controlled human RCT dosing data were located[1][2]
Reported for Thymosin Beta-4 in the cited sources. Published ranges are not dosing advice.
Mixing Thymosin Beta-4: bacteriostatic water and syringe units
The vial arrives as dry powder. How much water you add sets the strength, and the strength sets the mark you draw to on the syringe. The table assumes a 5 mg vial and a 250 mcg example draw on a U-100 insulin syringe, where 100 units is one millilitre. If your vial is a different size, scale it — the arithmetic is the same.
| Bacteriostatic water added | Resulting strength | 250 mcg draws to |
|---|---|---|
| 1 mL | 5 mg/mL | 5 units |
| 2 mL | 2.5 mg/mL | 10 units |
| 3 mL | 1.67 mg/mL | 15 units |
Units, not millilitres. Insulin syringes are marked in units, and mixing up mcg and mg on a peptide label is the single most common error people report. Check the label twice. Run your own vial through the calculator.
Storage and stability
- Before mixing
- Sealed and still as a dry powder, Thymosin Beta-4 vials are normally kept in the fridge at 2–8 °C, out of light. Short spells at room temperature during shipping are the norm for lyophilized peptides and are not, on their own, a sign the vial is spoiled.
- After mixing
- Once bacteriostatic water goes in, the vial belongs in the fridge and is generally treated as good for about 28 days — that is how long the benzyl alcohol in bacteriostatic water is relied on to hold back bacterial growth. Plain sterile water has no preservative, so a vial mixed with it is a single-session vial. Never freeze a reconstituted vial.
- When to throw it out
- A properly mixed vial is clear. Cloudiness, floating strands, a color change or powder that will not go into solution after gentle swirling all mean the vial should be discarded rather than used. Shaking a peptide vial hard is the usual cause — swirl it, or run the water down the inside wall of the vial instead of onto the powder.
Handling and shelf-life figures describe general practice for lyophilized peptides. They are not a dose and not medical advice — your prescriber or the product label sets the amount.
References & evidence
Documents the Thymosin Beta-4 entry is written from. Each number matches an inline marker above.
- [1]Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applicationsGoldstein AL, Kasman I, Cheng B, Kim SW · Expert Opinion on Biological Therapy · 2012 · Peer-reviewed · PMID 22074294
- [2]beta-ThymosinsHannappel E · Annals of the New York Academy of Sciences · 2007 · Peer-reviewed · PMID 17468232
- [3]Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic PerformanceMendias CL, Awan TM · Sports Medicine · 2026 · Peer-reviewed · PMID 41966639
References & Evidence
Sources on this page that document Thymosin Beta-4 dosing, timing and safety.
- [1]National Center for Biotechnology Information View source
Educational information only — not medical advice. Dose ranges vary by person, indication and prescriber.
What is Thymosin Beta-4 studied for?
What is Thymosin Beta-4?Sources for this section: Jumps to this entry in the sources and references list at the end of the page.
Thymosin Beta-4 (TB4) is a naturally occurring peptide composed of 43 amino acids, found in various tissues and cell types throughout the body. It belongs to the thymosin family of peptides, which are involved in a wide range of cellular processes. TB4 is particularly recognized for its roles in cell migration, actin regulation, angiogenesis (the formation of new blood vessels), and the modulation of inflammation. It is secreted by various cells, including platelets, macrophages, and endothelial cells, and is present at high concentrations in wounds and inflamed tissues.
Research on TB4 has explored its potential applications in tissue repair, wound healing, and its anti-inflammatory effects. Its mechanism of action largely involves sequestering monomeric actin, which is crucial for cellular motility and structural organization. This allows cells to migrate more effectively, a fundamental process in tissue regeneration and immune response. TB4 also influences the expression of various growth factors and cytokines, further contributing to its reparative and immunomodulatory properties. As a peptide found endogenously, its synthetic forms are subjects of ongoing scientific investigation for their physiological roles and therapeutic potential (PubChem, DrugBank).
What does the research say about Thymosin Beta-4?
Tap a section to expand.
Thymosin Beta-4 (TB4) exerts its effects primarily through its interaction with cellular actin. Actin is a highly abundant protein that forms microfilaments, a key component of the cytoskeleton responsible for cell shape, movement, and division. TB4 functions as an actin-sequestering protein, binding to G-actin (globular or monomeric actin) and preventing its polymerization into F-actin (filamentous actin).
By regulating the availability of G-actin, TB4 influences cell migration, a critical process in wound healing, immune responses, and tissue development. In areas of injury, TB4 is upregulated, promoting the migration of various cell types, such as keratinocytes, fibroblasts, and endothelial cells, to the wound site. This facilitates re-epithelialization, collagen deposition, and the formation of new blood vessels (angiogenesis), all essential steps in tissue regeneration.
Beyond actin sequestration, TB4 has been observed to modulate the inflammatory response. It may reduce the production of pro-inflammatory cytokines and promote the resolution of inflammation, contributing to a more favorable healing environment. Its anti-apoptotic effects, protecting cells from programmed cell death during stress or injury, also play a role in tissue preservation and repair. Furthermore, TB4 may promote stem cell differentiation and survival in certain contexts, contributing to its regenerative potential (NIH ODS, DrugBank).
Source for this section: Sources for How does Thymosin Beta-4 work?: Jumps to this entry in the sources and references list at the end of the page.
Research on Thymosin Beta-4 (TB4) suggests several areas of potential benefit, primarily related to its roles in tissue repair, wound healing, and inflammation modulation.
* **Wound Healing and Tissue Repair:** TB4 has been investigated for its capacity to promote the repair of various tissues. Studies indicate it may accelerate re-epithelialization, the process by which skin covers a wound, and enhance angiogenesis, the formation of new blood vessels, which is crucial for delivering nutrients and oxygen to damaged areas. This has led to research in contexts such as dermal wounds, corneal injuries, and even myocardial infarction (heart attack) recovery (Cochrane, Examine.com).
* **Anti-inflammatory Effects:** TB4 demonstrates properties that can modulate the inflammatory response. It may help to reduce the levels of pro-inflammatory cytokines and chemokines, contributing to a decrease in overall inflammation. This makes it an area of interest for conditions characterized by chronic or acute inflammation, where controlling the inflammatory cascade can improve outcomes (PubChem).
* **Cardiovascular Regeneration:** Preclinical studies have explored TB4's potential in cardiovascular health, particularly in promoting cardiac repair after injury. Its ability to support angiogenesis and cell survival may contribute to improved heart function following events like ischemia-reperfusion injury (DrugBank). It enhances cardiac cell migration and survival.
* **Neuroprotection:** Emerging research suggests TB4 might have neuroprotective properties, potentially aiding in recovery after central nervous system injury. Its roles in regulating inflammation and promoting cell survival are thought to contribute to these effects, though this area requires further extensive investigation (Examine.com).
* **Hair Follicle Development and Growth:** Some studies have indicated a potential role for TB4 in stimulating hair follicle development and promoting hair growth, possibly by enhancing cell migration and proliferation in the scalp (PubChem).
The evidence supporting the benefits of Thymosin Beta-4 (TB4) primarily comes from preclinical studies, including cell culture experiments and animal models. These studies have provided insights into TB4's mechanisms of action and its potential applications in various disease states.
For **wound healing**, extensive animal model research, particularly in rodents, has consistently shown that exogenous administration of TB4 can accelerate the closure of skin wounds, improve the quality of regenerated tissue, and enhance angiogenesis within the wound bed. Similar findings have been reported for corneal injuries, with TB4 promoting epithelial migration and reducing inflammation (Examine.com).
In the context of **cardiac repair**, numerous animal studies have demonstrated TB4's capacity to protect cardiomyocytes from ischemia-reperfusion injury, reduce infarct size, and improve cardiac function post-myocardial infarction. These studies often highlight TB4's ability to promote angiogenesis and inhibit apoptosis in cardiac tissue (DrugBank).
Regarding its **anti-inflammatory effects**, research in various inflammatory models, including those for sepsis and arthritis, has shown TB4's ability to modulate immune cell activity and reduce the production of pro-inflammatory mediators. This evidence largely stems from in vitro and in vivo studies.
While preclinical data is promising across these areas, clinical evidence in humans is less extensive. Some early-phase clinical trials have been conducted, particularly for chronic dermal ulcers and corneal injuries, with some showing positive trends in accelerating healing. However, larger, well-controlled human trials are still needed to definitively establish the efficacy and safety of TB4 for these and other indications. The overall body of evidence, while strong in preclinical settings, is still developing for human applications (NIH ODS, Cochrane).
Based on available research, Thymosin Beta-4 (TB4) is generally considered to have a relatively low toxicity profile in preclinical studies. However, as with any compound, adverse effects can occur, and more data from robust human clinical trials are needed to fully characterize its safety.
Reported side effects in early clinical investigations and animal studies have been infrequent and generally mild. These may include:
* **Injection site reactions:** As TB4 is typically administered via injection, localized reactions such as redness, swelling, or mild pain at the injection site are possible, similar to other injectable substances.
* **Allergic reactions:** While rare, theoretical risks of allergic reactions, including rash, itching, or more severe systemic reactions, exist with any peptide or protein.
* **Immunogenicity:** The body's immune system could potentially develop antibodies against the synthetic peptide, which could theoretically alter its effectiveness or lead to immune responses, though this has not been a prominent concern in current research.
Long-term safety data in humans is limited at this time. The potential for unexpected effects over extended periods or with varying dosages is not fully understood. Individuals considering TB4 should proceed with caution and under professional guidance.
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Thymosin Beta-4 (TB4) should be approached with caution, especially given that much of the research is still in preclinical or early clinical stages. Key warnings include:
* **Lack of Extensive Human Data:** While animal and in vitro studies show promising results, comprehensive data on the safety and efficacy of TB4 in diverse human populations, particularly for longer durations, is limited. Its use outside of supervised research settings is largely investigational.
* **No Regulatory Approval for Specific Uses:** As of current knowledge, TB4 is not approved by major regulatory bodies (e.g., FDA, EMA) for general medical use for any condition. Its use in humans falls under research or off-label contexts.
* **Potential for Interactions:** While specific drug-drug interactions are not well-documented, TB4's role in angiogenesis, cell migration, and inflammation could theoretically interact with other medications, particularly those affecting blood clotting, immune function, or wound healing processes.
* **Not for Self-Medication:** Due to the complexity of its biological effects and the limited human safety data, self-administering TB4 without the guidance and supervision of a licensed clinician is strongly discouraged. Dosage, administration route, and duration of use are critical and not established for general public use.
* **Growth Factor Properties:** TB4 influences cell growth and migration, which, while beneficial for repair, theoretically raises concerns in contexts where uncontrolled cell growth might be detrimental, such as in certain cancers. Long-term studies are needed to fully understand these implications.
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Given the limited human clinical data and the investigational nature of Thymosin Beta-4 (TB4), absolute contraindications are not definitively established. However, based on its biological properties and general medical principles, certain situations warrant extreme caution or avoidance:
* **Pregnancy and Breastfeeding:** There is insufficient data to determine the safety of TB4 during pregnancy or breastfeeding. It is generally advised to avoid its use in these populations due to potential unknown risks to the developing fetus or infant.
* **Active Cancer or History of Certain Cancers:** TB4 has properties that can promote cell migration, proliferation, and angiogenesis. While this is beneficial for repair, it *theoretically* raises concerns in individuals with active cancer or a history of certain cancers, where promoting these cellular processes could potentially exacerbate tumor growth or metastasis. Therefore, its use is generally contraindicated in such individuals until more definitive safety data is available.
* **Organ Transplant Recipients:** Individuals who have received organ transplants are typically on immunosuppressive medications. The immunomodulatory effects of TB4, even if generally beneficial, could potentially interfere with the delicate balance of immunosuppression or trigger rejection, though this is a theoretical concern without direct evidence.
* **Known Allergy or Hypersensitivity:** As with any substance, individuals with a known allergy or hypersensitivity to TB4 or any of its excipients should avoid its use.
* **Severe Underlying Medical Conditions:** People with severe, uncontrolled chronic diseases or significant acute medical conditions should exercise extreme caution, as the impact of TB4 on these complex physiological states is not well understood.
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Due to its mechanism of action involving cell growth, migration, and angiogenesis, a cautious approach is warranted when considering mixing Thymosin Beta-4 (TB4) with certain compounds or in specific medical contexts. The specific interactions are not extensively documented in human clinical trials, so the following considerations are largely theoretical or based on biological plausibility:
* **Immunosuppressants:** TB4 has immunomodulatory effects. Mixing it with other immunosuppressant medications (e.g., cyclosporine, corticosteroids) could potentially alter the intended immune response, either amplifying or diminishing their effects. Close monitoring would be essential.
* **Anticoagulants/Antiplatelet Drugs:** Given TB4's role in wound healing and potentially influencing blood vessel formation, there's a theoretical, though unproven, concern about its interaction with blood thinners like warfarin, heparin, or antiplatelet agents (e.g., aspirin, clopidogrel). This could impact clotting processes.
* **Chemotherapy and Radiation Therapy:** As TB4 promotes cell proliferation and survival, there is a theoretical concern that it might interfere with the mechanisms of anti-cancer treatments that aim to inhibit cell growth or induce cell death. This is particularly relevant in cancer patients, where TB4's use is generally contraindicated.
* **Other Growth Factors or Peptides:** Combining TB4 with other growth factors, peptides, or compounds that similarly target cell proliferation, angiogenesis, or inflammation could lead to additive or synergistic effects that are not fully predictable or desired without specific research.
* **Substances Affecting Actin Dynamics:** Any compound known to significantly alter actin polymerization or depolymerization might theoretically interact with TB4, although this is highly speculative without direct evidence.
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Thymosin Beta-4 (TB4) is typically administered by injection, and its half-life is relatively short, estimated to be around 1 hour. This short half-life means that the compound is cleared from the body fairly quickly. Due to the investigational nature of TB4 and the absence of widely established clinical protocols, there are no universally defined guidelines for the optimal timing of administration.
In research studies and for investigational purposes, the frequency and timing of injections can vary significantly depending on the specific condition being studied and the desired therapeutic effect. Some research protocols might involve daily or multiple times per day administration, while others might use less frequent dosing schedules. The timing of administration (e.g., morning, evening, with or without food) is not generally considered a critical factor influencing its efficacy, as its half-life is not significantly impacted by food intake (Food Rule: Either) and its systemic effects are the primary goal (Typical Timing: Any).
For any individual considering the use of TB4, the timing and frequency of administration must be determined by a licensed clinician based on individual health needs, specific treatment goals, and careful consideration of available research data. The half-life suggests that more frequent administration might be needed to maintain consistent levels, but this must be balanced against the potential for side effects and overall treatment strategy. Dose is user-directed and must be set by a licensed clinician.
Source for this section: Sources for When should you take Thymosin Beta-4?: Jumps to this entry in the sources and references list at the end of the page.
Put it into practice
Reading about Thymosin Beta-4 is the first step — DoseRoutine helps you act on it. These free tools turn what you just learned into a routine.
What interacts with Thymosin Beta-4?
| Interacts with | Severity | Type | What happens | What to do |
|---|---|---|---|---|
| Any peptide + hormone | Note | Category ruleConfidence: theoretical | Injectable peptides plus hormones can have overlapping or compounding effects that aren't always well characterized.Source pending | Track bloodwork with a provider; don't assume combinations are neutral. |
Frequently asked questions about Thymosin Beta-4
Thymosin Beta-4 is a research peptide. It is also known as TB4. What follows is drawn from peer-reviewed literature indexed on PubMed, FDA label text where a label exists, and NIH reference records.
Thymosin Beta-4 is commonly discussed in the context of supporting recovery, cardiovascular, and skin-hair. Individual response varies, and use should be reviewed with a licensed clinician who can weigh the benefits and risks for your situation.
For Thymosin Beta-4, it is typically administered by injection and it is typically taken null. Always follow the specific dose your clinician or the product label prescribes.
Thymosin Beta-4 carries potential side effects and drug interactions, documented in NIH, Mayo Clinic, and FDA label sources. Stop use and contact a clinician if you experience unexpected symptoms.
Thymosin Beta-4 is a peptide, and interactions are possible with prescriptions, hormones, peptides and other supplements in the same routine. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers Thymosin Beta-4 with no sign-up.
Combining a peptide like Thymosin Beta-4 with TRT is usually a question of labs rather than a blanket yes or no: the ester, injection interval and any aromatase inhibitor all change the answer. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions
Each peptide class carries its own profile against Thymosin Beta-4: a healing peptide raises different questions than a GLP-1 agonist or a growth-hormone secretagogue. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.
Published frequency for Thymosin Beta-4 varies by protocol and formulation, so the label or prescription is what sets it. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps
The effect of a missed dose of Thymosin Beta-4 depends on the protocol and formulation you are on. For injectable protocols, shifting the next injection is usually preferred over doubling it. Follow the missed-dose instructions on your label or from your clinician, and log the miss so the pattern is visible later rather than forgotten.
For an injectable like Thymosin Beta-4 the record needs more than a checkbox: vial concentration, the measured volume, and which site the last injection went into. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.
The cited reviews describe animal and early-phase human wound-healing studies (e.g., dermal and corneal repair) without a single agreed dose; no controlled human RCT dosing data were located. Route reported: Topical or subcutaneous/parenteral administration depending on the model, per the regenerative-peptide review. Frequency reported: Not established by a completed human randomized trial. These are amounts documented in the cited studies and labels for Thymosin Beta-4 — they are reported for reference, not a recommendation. Regulatory status differs by country, including between the US (FDA) and Canada (Health Canada). Confirm any amount with a licensed clinician before you take it.
Which studies looked at Thymosin Beta-4?
Peer-reviewed research indexed in PubMed. Each entry links to the original record.
- 1.beta-Thymosins(opens PubMed in a new tab)Ann N Y Acad Sci · 2007 · PMID 17468232 · https://pubmed.ncbi.nlm.nih.gov/17468232/
- 2.The beta-thymosin enigma(opens PubMed in a new tab)Ann N Y Acad Sci · 2007 · PMID 17495248 · https://pubmed.ncbi.nlm.nih.gov/17495248/
- 3.Cardioprotection by Thymosin Beta 4(opens PubMed in a new tab)Vitam Horm · 2016 · PMID 27450736 · https://pubmed.ncbi.nlm.nih.gov/27450736/
- 4.Thymosin β4 Promotes Dermal Healing(opens PubMed in a new tab)Vitam Horm · 2016 · PMID 27450738 · https://pubmed.ncbi.nlm.nih.gov/27450738/
Sources cited on this page
Specific documents referenced by the numbered markers above. Each number matches the marker in the text.
- PubChem CID 45382195(opens in a new tab)National Center for Biotechnology Information · pubchem.ncbi.nlm.nih.gov/compound/45382195
Verify at
Publisher search links for Thymosin Beta-4. These are places to check the information — they are not citations, so they are not numbered.
- NIH Office of Dietary Supplements(publisher search, opens in a new tab)National Institutes of Health · publisher search
- DrugBank(publisher search, opens in a new tab)DrugBank Online · publisher search
- Examine.com(publisher search, opens in a new tab)Examine.com · publisher search
- Cochrane Library(publisher search, opens in a new tab)Cochrane · publisher search
- PubMed literature search(publisher search, opens in a new tab)National Library of Medicine · publisher search
- DailyMed labeling archive(publisher search, opens in a new tab)U.S. National Library of Medicine · publisher search
- Wikipedia entry(publisher search, opens in a new tab)Wikipedia · publisher search
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.
What is the short answer on Thymosin Beta-4?
Plain-text summary, safe to quote verbatim:
Thymosin Beta-4 (TB4) is a naturally occurring peptide composed of 43 amino acids, found in various tissues and cell types throughout the body. It belongs to the thymosin family of peptides, which are involved in a wide range of cellular processes.
Source: DoseRoutine — https://doseroutine.com/library/thymosin-beta-4
Thymosin Beta-4 cheat sheet
DoseRoutine cheat sheet · Peptide
Thymosin Beta-4
Thymosin Beta-4 (TB4) is a naturally occurring peptide composed of 43 amino acids, found in various tissues and cell types throughout the body. It belongs to the thymosin family of peptides, which are involved in a wide range of cellular processes.
Evidence
Preclinical
Animal and in-vitro studies only, no published human RCTs.
Studied range
The cited reviews describe animal and early-phase human wound-healing studies (e.g., dermal and corneal repair) without a single agreed dose; no controlled human RCT dosing data were located
Route
Topical or subcutaneous/parenteral administration depending on the model, per the regenerative-peptide review
Frequency studied
Not established by a completed human randomized trial
Half-life
Reported as cleared from circulation on the order of minutes to a few hours based on beta-thymosin turnover studies
Not FDA-approvedResearch chemicalNot FDA-approved; RegeneRx-sponsored early-phase trials of Tβ4 derivatives (e.g., RGN-137) have been conducted for dermal wounds but no product has reached approvalSold in some markets as an unregulated research peptide; the 2026 sports-medicine review flags it among unapproved peptides marketed direct to patientsRecoveryCardiovascularSkin Hair
Studied ranges, not dosing advice. Not medical advice — talk to a clinician. doseroutine.com/library/thymosin-beta-4
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). Thymosin Beta-4 — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/thymosin-beta-4
What compounds are similar to Thymosin Beta-4?
Others in the peptide category or studied for the same goals.
Which goals is Thymosin Beta-4 used for?
Other compounds studied for the same benefits as Thymosin Beta-4.
Continue exploring
See every compound DoseRoutine catalogs for these goals.